August 27, 2016 4:53 AM ET

Pharmaceuticals

Company Overview of Nektar Therapeutics

Executive Profile

Gene D. Resnick M.D.

Member of Oncology Advisory Committee, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 3 different industries.

See Board Relationships
67--

Background

Dr. Gene D. Resnick, M.D. served as the Chief Medical Officer and Executive Vice President of Aptiv Solutions. Dr. Resnick served as President of Millennix Oncology Division of Averion International Corp. since July 2006. Dr. Resnick served as Chief Medical Officer of IT&E International Group Inc. since March 14, 2006 and as its Senior Vice President since November 2005 & its Vice President. He founded Millennix Inc. in 1997 and served as its President & Chief Executive ...

Corporate Headquarters

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships

Chairman
Director

Education

BS
New York Hospital-Cornell Medical Center
MD
New York Hospital-Cornell Medical Center
BS
Cornell University
MD 1974
Weill Cornell Medical College, New York

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President, Director and Member of Stock Option Committee
Innoviva, Inc.
$721.4K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
Depomed, Inc.
$708.3K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science Committee
Progenics Pharmaceuticals, Inc.
$597.1K
Peter S. Greenleaf Chairman and Chief Executive Officer
Sucampo Pharmaceuticals, Inc.
$565.3K
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nektar Therapeutics, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.